---
layout: post
title: "Multiple Endpoints in Clinical Trials; Guidance for Industry; Availability"
date: 2026-02-05 19:01:13 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-22882
original_published: 2022-10-21 00:00:00 +0000
significance: 8.00
---

# Multiple Endpoints in Clinical Trials; Guidance for Industry; Availability

**Published:** February 05, 2026 19:01 UTC
**Source:** Federal Register
**Original Published:** October 21, 2022 00:00 UTC
**Document Number:** 2022-22882

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Multiple Endpoints in Clinical Trials." This guidance provides sponsors and review staff with the Agency's thinking about the problems posed by multiple endpoints in the analysis and interpretation of study results and how these problems can be managed in clinical trials for human drugs, including drugs subject to licensing as biological products. This guidance finalizes the draft guidance of the same title issued on January 13, 2017.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/10/21/2022-22882/multiple-endpoints-in-clinical-trials-guidance-for-industry-availability)
- API: https://www.federalregister.gov/api/v1/documents/2022-22882

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
